spacer
home > ebr > autumn 2018 > applying affimers
PUBLICATIONS
European Biopharmaceutical Review

Applying Affimers

Pharmacokinetic (PK) assays are a key component of drug development and clinical follow-up processes, with the global PK assay service market currently valued at US $652.8 million (1). Results from PK assays are critical in all phases of drug development, and numerous decisionmaking milestones in drug development programmes rely, at least in part, on PK assay results and the exposure-response relationships based on pharmacodynamic (PD) endpoints or clinical endpoints. Companies are increasingly using data from drug monitoring assays at all stages of the development pipeline to enhance the productivity and efficiency of new drug development processes (2).

Both PK and PD assays require critical reagents (eg, anti-drug reagents/anti-idiotypic binders) that can specifically and accurately measure the drug in plasma and tissues. Sensitive and reproducible PK assays are required as part of the complex and lengthy development process for new therapeutic molecules. These drug monitoring assays must be well-characterised, fully validated, and documented to yield reliable results compliant with the necessary regulatory standards.

Antibodies currently represent the ‘gold standard’ of affinity reagents, and, while traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable, these can be limited by development speed, complexity to produce on an industrial scale, and lotto- lot variation in assay performance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Amanda Nicholl is Senior Assay Development Scientist at Avacta, where she applies her experience in molecular and cellular biology in both academic and industrial environments to develop assays and generate data to exemplify the use of affimer technology.
spacer
Dr Amanda Nicholl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms

Teknomek Ltd

Teknomek explains why stainless steel is the material of choice for laboratories and hygienic manufacturing.
More info >>

 
Industry Events

2019 PDA Annual Meeting

11-13 March 2019, Marriot Marquis San Diego, CA

Get the most current and comprehensive information on pharmaceutical processing, manufacturing, supply chain, and quality control. Benefit from plenary sessions, concurrent tracks, topic-specific Interest Group sessions, an exhibition, and networking opportunities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement